Spark Therapeutics IPO Info
Company Name: Spark Therapeutics
Stock Symbol: ONCE
Exchange: NASDAQ
Status: Priced
IPO Date: 1/30/2015
IPO Price:
23.00 (
97.00%)
Underwriters
J.P. Morgan and Credit Suisse
Amount of Offering: N/A
Number of Shares Offered: 7 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Spark Therapeutics is a leader in the field of gene therapy, seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. The company's product candidates have the potential to provide long-lasting effects, dramatically and positively changing the lives of patients with conditions where no, or only palliative, therapies exist. The company's initial focus is on treating orphan diseases, and they have demonstrated promising clinical outcomes with their first product candidate targeting rare blinding conditions, which has received both breakthrough therapy and orphan product designation and is in a fully enrolled, pivotal Phase 3 clinical trial with data expected in the second half of 2015. They have also have built a pipeline of product candidates targeting additional blinding conditions, hematologic disorders and neurodegenerative diseases, including a second product candidate targeting another rare blinding condition, for which they expect to initiate a clinical trial in the first half of 2015, and a collaboration with Pfizer Inc., or Pfizer, for the development and commercialization of a gene therapy for the treatment of hemophilia B. The company's platform technology is based on more than two decades of gene therapy research, development, manufacturing and clinical trials conducted at The Children�s Hospital of Philadelphia, or CHOP.
SEC Filings
News Headlines
